Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selexipag for Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)
2014-000865-34Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Raynaud disease comparing Selexipag with Placebo (2 arms). Primary endpoint: Average weekly number of Raynaud's phenomenon attacks during maintenance period. Started Sep 2014; status: completed.
02
Drugs
selexipag
03
Conditions
Raynaud disease
Beyond the preview
Go deeper on 2014-000865-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000865-34.